(Reuters) - Bristol-Myers Squibb Co said the independent data monitoring committee concluded that a late stage study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer met its endpoint. The company said the data demonstrates superior overall survival in patients receiving Opdivo compared to the control arm, indicating a survival advantage with an anti-PD1 immune checkpoint inhibitor in lung cancer. Bristol-Myers stopped the comparative portion of the trial and said it will share the data with health authorities. ... via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment